Hubbry Logo
Sex-determining region Y proteinSex-determining region Y proteinMain
Open search
Sex-determining region Y protein
Community hub
Sex-determining region Y protein
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Sex-determining region Y protein
Sex-determining region Y protein
Sex-determining region Y protein
View on Wikipedia
from Wikipedia
"SRY" redirects here. For other uses, see SRY (disambiguation).
For a broader background, see Sexual differentiation in humans.

SRY
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesSRY, SRXX1, SRXY1, TDF, TDY, Testis determining factor, sex determining region Y, Sex-determining region of Y-chromosome, Sex-determining region Y
External IDsOMIM: 480000; MGI: 98660; HomoloGene: 48168; GeneCards: SRY; OMA:SRY - orthologs
Orthologs
SpeciesHumanMouse
Entrez

6736

21674

Ensembl

ENSG00000184895

ENSMUSG00000069036

UniProt

Q05066

Q05738

RefSeq (mRNA)

NM_003140

NM_011564

RefSeq (protein)

NP_003131

NP_035694

Location (UCSC)Chr Y: 2.79 – 2.79 MbChr Y: 2.66 – 2.66 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

In humans, the SRY gene is located on short (p) arm of the Y chromosome at position 11.2

Sex-determining region Y protein (SRY), or testis-determining factor (TDF), is a DNA-binding protein (also known as gene-regulatory protein/transcription factor) encoded by the SRY gene that is responsible for the initiation of male sex determination in therian mammals (placentals and marsupials).[5] SRY is an intronless sex-determining gene on the Y chromosome.[6] Mutations in this gene lead to a range of disorders of sex development with varying effects on an individual's phenotype and genotype.

SRY is a member of the SOX (SRY-like box) gene family of DNA-binding proteins. When complexed with the steroidogenic factor 1 (SF-1) protein, SRY acts as a transcription factor that causes upregulation of other transcription factors, most importantly SOX9.[7] Its expression causes the development of primary sex cords, which later develop into seminiferous tubules. These cords form in the central part of the yet-undifferentiated gonad, turning it into a testis. The now-induced Leydig cells of the testis then start secreting testosterone, while the Sertoli cells produce anti-Müllerian hormone.[8] Effects of the SRY gene, which normally take place 6–8 weeks after fetus formation, inhibit the growth of female anatomical structure in males. The gene also contributes towards developing the secondary sexual characteristics of males.[9]

Gene evolution and regulation

[edit]

Evolution

[edit]

SRY may have arisen from a gene duplication of the X chromosome bound gene SOX3, a member of the SOX family.[10][11] This duplication occurred after the split between monotremes and therians. Monotremes lack SRY and some of their sex chromosomes share homology with bird sex chromosomes.[12] SRY is a quickly evolving gene, and its regulation has been difficult to study because sex determination is not a highly conserved phenomenon within the animal kingdom.[13] Even within marsupials and placentals, which use SRY in their sex determination process, the action of SRY differs between species.[11] The gene sequence also changes; while the core of the gene, the high-mobility group (HMG) box, is conserved between species, other regions of the gene are not.[11] SRY is one of only four genes on the human Y chromosome that have been shown to have arisen from the original Y chromosome.[14] The other genes on the human Y chromosome arose from an autosome that fused with the original Y chromosome.[14]

Regulation

[edit]

SRY has little in common with sex determination genes of other model organisms, therefore, mice are the main model research organisms that can be utilized for its study. Understanding its regulation is further complicated because even between mammalian species, there is little protein sequence conservation. The only conserved group in mice and other mammals is the HMG box region that is responsible for DNA binding. Mutations in this region result in sex reversal, where the opposite sex is produced.[15] Because there is little conservation, the SRY promoter, regulatory elements and regulation are not well understood. Within related mammalian groups there are homologies within the first 400–600 base pairs (bp) upstream from the translational start site. In vitro studies of human SRY promoter have shown that a region of at least 310 bp upstream to translational start site are required for SRY promoter function. It has been shown that binding of three transcription factors, steroidogenic factor 1 (SF1), specificity protein 1 (Sp1 transcription factor) and Wilms tumor protein 1 (WT1), to the human promoter sequence, influence expression of SRY.[15]

The promoter region has two Sp1 binding sites, at -150 and -13 that function as regulatory sites. Sp1 is a transcription factor that binds GC-rich consensus sequences, and mutation of the SRY binding sites leads to a 90% reduction in gene transcription. Studies of SF1 have resulted in less definite results. Mutations of SF1 can lead to sex reversal, and deletion can lead to incomplete gonad development. However, it is not clear how SF1 interacts with the SR1 promoter directly.[16] The promoter region also has two WT1 binding sites at -78 and -87 bp from the ATG codon. WT1 is transcription factor that has four C-terminal zinc fingers and an N-terminal Pro/Glu-rich region and primarily functions as an activator. Mutation of the zinc fingers or inactivation of WT1 results in reduced male gonad size. Deletion of the gene resulted in complete sex reversal. It is not clear how WT1 functions to up-regulate SRY, but some research suggests that it helps stabilize message processing.[16] However, there are complications to this hypothesis, because WT1 also is responsible for expression of an antagonist of male development, DAX1, which stands for dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1. An additional copy of DAX1 in mice leads to sex reversal. It is not clear how DAX1 functions, and many different pathways have been suggested, including SRY transcriptional destabilization and RNA binding. There is evidence from work on suppression of male development that DAX1 can interfere with function of SF1, and in turn transcription of SRY by recruiting corepressors.[15]

There is also evidence that GATA binding protein 4 (GATA4) and FOG2 contribute to activation of SRY by associating with its promoter. How these proteins regulate SRY transcription is not clear, but FOG2 and GATA4 mutants have significantly lower levels of SRY transcription.[17] FOGs have zinc finger motifs that can bind DNA, but there is no evidence of FOG2 interaction with SRY. Studies suggest that FOG2 and GATA4 associate with nucleosome remodeling proteins that could lead to its activation.[18]

Function

[edit]

During gestation, the cells of the primordial gonad that lie along the urogenital ridge are in a bipotential state, meaning they possess the ability to become either male cells (Sertoli and Leydig cells) or female cells (follicle cells and theca cells). SRY initiates testis differentiation by activating male-specific transcription factors that allow these bipotential cells to differentiate and proliferate. SRY accomplishes this by upregulating SOX9, a transcription factor with a DNA-binding site very similar to SRY's. SOX9 leads to the upregulation of fibroblast growth factor 9 (Fgf9), which in turn leads to further upregulation of SOX9. Once proper SOX9 levels are reached, the bipotential cells of the gonad begin to differentiate into Sertoli cells. Additionally, cells expressing SRY will continue to proliferate to form the primordial testis. This brief review constitutes the basic series of events, but there are many more factors that influence sex differentiation.

Action in the nucleus

[edit]

The SRY protein consists of three main regions. The central region encompasses the high-mobility group (HMG) domain, which contains nuclear localization sequences and acts as the DNA-binding domain. The C-terminal domain has no conserved structure, and the N-terminal domain can be phosphorylated to enhance DNA-binding.[16] The process begins with nuclear localization of SRY by acetylation of the nuclear localization signal regions, which allows for the binding of importin β and calmodulin to SRY, facilitating its import into the nucleus. Once in the nucleus, SRY and SF1 (steroidogenic factor 1, another transcriptional regulator) complex and bind to TESCO (testis-specific enhancer of Sox9 core), the testes-specific enhancer element of the Sox9 gene in Sertoli cell precursors, located upstream of the Sox9 gene transcription start site.[7] Specifically, it is the HMG region of SRY that binds to the minor groove of the DNA target sequence, causing the DNA to bend and unwind. The establishment of this particular DNA "architecture" facilitates the transcription of the Sox9 gene.[16] In the nucleus of Sertoli cells, SOX9 directly targets the Amh gene as well as the prostaglandin D synthase (Ptgds) gene. SOX9 binding to the enhancer near the Amh promoter allows for the synthesis of Amh while SOX9 binding to the Ptgds gene allows for the production of prostaglandin D2 (PGD2). The reentry of SOX9 into the nucleus is facilitated by autocrine or paracrine signaling conducted by PGD2.[19] SOX9 protein then initiates a positive feedback loop, involving SOX9 acting as its own transcription factor and resulting in the synthesis of large amounts of SOX9.[16]

SOX9 and testes differentiation

[edit]

The SF-1 protein, on its own, leads to minimal transcription of the SOX9 gene in both the XX and XY bipotential gonadal cells along the urogenital ridge. However, binding of the SRY-SF1 complex to the testis-specific enhancer (TESCO) on SOX9 leads to significant up-regulation of the gene in only the XY gonad, while transcription in the XX gonad remains negligible. Part of this up-regulation is accomplished by SOX9 itself through a positive feedback loop; like SRY, SOX9 complexes with SF1 and binds to the TESCO enhancer, leading to further expression of SOX9 in the XY gonad. Two other proteins, FGF9 (fibroblast growth factor 9) and PDG2 (prostaglandin D2), also maintain this up-regulation. Although their exact pathways are not fully understood, they have been proven to be essential for the continued expression of SOX9 at the levels necessary for testes development.[7]

SOX9 and SRY are believed to be responsible for the cell-autonomous differentiation of supporting cell precursors in the gonads into Sertoli cells, the beginning of testes development. These initial Sertoli cells, in the center of the gonad, are hypothesized to be the starting point for a wave of FGF9 that spreads throughout the developing XY gonad, leading to further differentiation of Sertoli cells via the up-regulation of SOX9.[20] SOX9 and SRY are also believed to be responsible for many of the later processes of testis development (such as Leydig cell differentiation, sex cord formation, and formation of testis-specific vasculature), although exact mechanisms remain unclear.[21] It has been shown, however, that SOX9, in the presence of PDG2, acts directly on Amh (encoding anti-Müllerian hormone) and is capable of inducing testis formation in XX mice gonads, indicating it is vital to testes development.[20]

SRY disorders' influence on sex expression

[edit]

Embryos are gonadally identical, regardless of genetic sex, until a certain point in development when the testis-determining factor causes male sex organs to develop. A typical male karyotype is XY, whereas a female's is XX. There are exceptions, however, in which SRY plays a major role. Individuals with Klinefelter syndrome inherit a normal Y chromosome and multiple X chromosomes, giving them a karyotype of XXY. Atypical genetic recombination during crossover, when a sperm cell is developing, can result in karyotypes that are not typical for their phenotypic expression.

Most of the time, when a developing sperm cell undergoes crossover during meiosis, the SRY gene stays on the Y chromosome. If the SRY gene is transferred to the X chromosome instead of staying on the Y chromosome, testis development will no longer occur. This is known as Swyer syndrome, characterized by an XY karyotype and a female phenotype. Individuals who have this syndrome have normally formed uteri and fallopian tubes, but the gonads are not functional. Swyer syndrome individuals are usually considered as females.[22] On the other spectrum, XX male syndrome occurs when a body has 46:XX Karyotype and SRY attaches to one of them through translocation. People with XX male syndrome have a XX Karyotype but are male.[23] Individuals with either of these syndromes can experience delayed puberty, infertility, and growth features of the opposite sex they identify with. XX male syndrome expressers may develop breasts, and those with Swyer syndrome may have facial hair.[22][24]

Klinefelter Syndrome
  • Inherit a normal Y chromosome and multiple X chromosomes, giving persons a karyotype of XXY.
  • Persons with this are considered male.
Swyer Syndrome
  • SRY gene is transferred to the X chromosome instead of staying on the Y chromosome, testis development will no longer occur.
  • Characterized by an XY karyotype and female phenotype.
  • Individuals have normally formed uteri and fallopian tubes, but the gonads are not functional.
XX Male Syndrome
  • Characterized by a body that has 46:XX Karyotype and SRY attaches to one of them through translocation.
  • Individuals have XX karyotype and male phenotype.

While the presence or absence of SRY has generally determined whether or not testis development occurs, it has been suggested that there are other factors that affect the functionality of SRY.[25] Therefore, there are individuals who have the SRY gene, but still develop as females, either because the gene itself is defective or mutated, or because one of the contributing factors is defective.[26] This can happen in individuals exhibiting a XY, XXY, or XX SRY-positive karyotype.

Additionally, other sex determining systems that rely on SRY beyond XY are the processes that come after SRY is present or absent in the development of an embryo. In a normal system, if SRY is present for XY, SRY will activate the medulla to develop gonads into testes. Testosterone will then be produced and initiate the development of other male sexual characteristics. Comparably, if SRY is not present for XX, there will be a lack of the SRY based on no Y chromosome. The lack of SRY will allow the cortex of embryonic gonads to develop into ovaries, which will then produce estrogen, and lead to the development of other female sexual characteristics.[27]

Role in other diseases

[edit]

SRY has been shown to interact with the androgen receptor and individuals with XY karyotype and a functional SRY gene can have an outwardly female phenotype due to an underlying androgen insensitivity syndrome (AIS).[28] Individuals with AIS are unable to respond to androgens properly due to a defect in their androgen receptor gene, and affected individuals can have complete or partial AIS.[29] SRY has also been linked to the fact that males are more likely than females to develop dopamine-related diseases such as schizophrenia and Parkinson's disease. SRY encodes a protein that controls the concentration of dopamine, the neurotransmitter that carries signals from the brain that control movement and coordination.[30] Research in mice has shown that a mutation in SOX10, an SRY encoded transcription factor, is linked to the condition of Dominant megacolon in mice.[31] This mouse model is being used to investigate the link between SRY and Hirschsprung disease, or congenital megacolon in humans.[31] There is also a link between SRY encoded transcription factor SOX9 and campomelic dysplasia (CD).[32] This missense mutation causes defective chondrogenesis, or the process of cartilage formation, and manifests as skeletal CD.[33] Two thirds of 46,XY individuals diagnosed with CD have fluctuating amounts of male-to-female sex reversal.[32]

Use in Olympic screening

[edit]
Further information: Sex verification in sports

One of the most controversial uses of this discovery was as a means for sex verification at the Olympic Games, under a system implemented by the International Olympic Committee in 1992. Athletes with an SRY gene were not permitted to participate as females, although all athletes in whom this was "detected" at the 1996 Summer Olympics were ruled false positives and were not disqualified. Specifically, eight female participants (out of a total of 3387) at these games were found to have the SRY gene. However, after further investigation of their genetic conditions, all these athletes were verified as female and allowed to compete. These athletes were found to have either partial or full androgen insensitivity, despite having an SRY gene, making them externally phenotypically female.[34] In the late 1990s, a number of relevant professional societies in United States called for elimination of gender verification, including the American Medical Association, stating that the method used was uncertain and ineffective.[35] Chromosomal screening was eliminated as of the 2000 Summer Olympics,[35][36][37] but this was later followed by other forms of testing based on hormone levels.[38] In March 2025 World Athletics announced it will do cheek swabbing tests for gender eligibility, specifically looking for the SRY gene, but that this would only be a first screen in determining eligibility, so that individuals with CAIS or Swyer's syndrome would not automatically be excluded from female competition.[9]

Ongoing research

[edit]

Despite the progress made during the past several decades in the study of sex determination, the SRY gene, and its protein, work is still being conducted to further understanding in these areas. There remain factors that need to be identified in the sex-determining molecular network, and the chromosomal changes involved in many other human sex-reversal cases are still unknown. Scientists continue to search for additional sex-determining genes, using techniques such as microarray screening of the genital ridge genes at varying developmental stages, mutagenesis screens in mice for sex-reversal phenotypes, and identifying the genes that transcription factors act on using chromatin immunoprecipitation.[16]

Fetal development-knockout models

[edit]

One of the knockout models for the SRY gene was done in pigs. Through the use of CRISPR technology the SRY gene was knocked out in male pigs. The target for the CRISPR technology is the high mobility group located on the SRY gene. The research showed that with the absence of SRY, both the internal and external genitalia were reversed. When the piglets were born they were phenotypically male but expressed female genitalia.[39] Another study done on mice used TALEN technology to produce an SRY knockout model. These mice expressed external and internal genitalia as well as a normal female level of circulating testosterone.[40] These mice, despite having XY chromosomes, expressed a normal estrus cycle albeit with reduced fertility. Both of these studies highlighted the role that SRY plays in the development of the testes and other male reproductive organs.

SRY knock-in

[edit]

CRISPR-Cas9 technology has been used to insert the SRY gene into XX individuals, thus creating a genetically female organism that is phenotypically male. Only a fragment of 14-kilobases of genomic DNA is necessary for the induction of testis. This alteration in addition to gene drives would allow for the induction of sterility to aid in population control of either unfavorable or invasive species. However, to utilize this knock-in, the relocation of the SRY gene onto the 17th chromosome (autosome) would be most efficient. These transgenic species would then be released into the wild to mate with the natural population, resulting in the creation of predominantly male offspring, thus decreasing reproductive rates. An autosomal SRY knock-in would result in a 75% SRY inheritance rate, whereas a 90% inheritance can be achieved when inserted into the t-complex on the 17th chromosome.[41] Although, previously unsuccessful in mammals, more recent research has found that although thought to only contain single exon for the last 30 years, a second SRY exon has been located named SRY-T .[42]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Sex-determining region Y protein

View on Grokipedia
from Grokipedia
The Sex-determining region Y protein (SRY) is a transcription factor encoded by the SRY gene on the short arm of the human Y chromosome that functions as the primary molecular switch initiating male gonad differentiation in therian mammals. By binding specific DNA sequences through its high-mobility group (HMG) box domain, SRY bends the DNA helix and activates downstream target genes, such as SOX9, promoting the development of Sertoli cells and thereby testis formation from the bipotential gonad around embryonic week 6-7 in humans. This process establishes the male developmental trajectory, suppressing ovarian pathways and enabling subsequent male reproductive tract morphogenesis under the influence of testicular hormones like testosterone and anti-Müllerian hormone. Identified in 1990 via positional cloning of Y-chromosomal regions translocated to X chromosomes in XX males, SRY was confirmed as the long-sought testis-determining factor (TDF) through transgenic experiments demonstrating its sufficiency to induce testis development in XY gonads and sex reversal in XX gonads. The protein's expression is transient, peaking in pre-Sertoli cells of the , and its dysfunction—often due to point mutations in the HMG box—results in syndromes like Swyer syndrome, where XY individuals develop as phenotypic females lacking functional gonads. While SRY's core role as a transcriptional activator is conserved across mammals, ongoing research explores nuanced mechanisms, including potential non-DNA-binding functions and regulatory elements influencing its spatiotemporal expression.

Discovery and Historical Context

Identification of the SRY Gene

The SRY gene was identified in 1990 through positional cloning on the short arm of the human (Yp11.3), within a region delimited by cytogenetic analysis of Y-to-autosome translocation breakpoints associated with 46,XX males and 46,XY females. This approach narrowed the candidate interval to approximately 35 kilobases, guided by prior mapping of the testis-determining factor (TDF) using familial XX males carrying Y-derived material and sporadic cases lacking functional Y sequences. The gene, named SRY for its location in the sex-determining region of the , was isolated from a screened with probes from conserved sequences in the minimal TDF region. Sequence analysis revealed that SRY encodes a 204-amino-acid protein featuring a high-mobility-group (HMG) box domain homologous to motifs in non-histone proteins involved in DNA bending and , suggesting a role as a sequence-specific DNA-binding factor. Compelling functional equivalence to TDF emerged from genetic evidence: de novo point mutations in SRY segregated with XY sex reversal in affected families, disrupting the HMG box and abolishing predicted DNA-binding activity, while XX males translocated Y material invariably included intact SRY sequences. These findings, reported concurrently by teams including Peter N. Goodfellow's group, established SRY as the mammalian TDF beyond reasonable doubt, as no other candidates in the region matched this mutational correlation. Subsequent transgenic experiments in confirmed SRY's sufficiency: introduction of a 14-kilobase genomic fragment containing mouse Sry into XX mouse embryos induced testis differentiation and development, directly demonstrating its causal role in gonadal sex determination. This identification resolved decades of search for the Y-linked sex switch, originally hypothesized from breeding studies in the early , and highlighted SRY's evolutionary derivation from family transcription factors.

Key Experimental Milestones

The identification of the SRY gene as the mammalian testis-determining factor culminated in positional cloning efforts targeting the minimal Y-chromosomal deletion interval associated with . In June 1990, Sinclair et al. isolated a 900-base-pair cDNA from the human Y chromosome's sex-determining region, encoding a protein featuring a high-mobility-group (HMG) box motif homologous to known DNA-binding domains in transcription factors. This sequence was conserved across species, including mice, suggesting a conserved role in male development. Genetic validation followed rapidly: in December 1990, Berta et al. sequenced SRY from two unrelated XY females with and identified distinct point mutations—one a G-to-A transition altering methionine-64 to , and another disrupting the HMG box—absent in normal males, establishing SRY mutations as causal for XY . These findings equated SRY with the long-sought testis-determining factor (TDF). Functional sufficiency was demonstrated in 1991 through transgenic experiments: Koopman et al. introduced a 14-kilobase genomic fragment containing the Sry gene into chromosomally female (XX) embryos, resulting in testis differentiation, male gonadal development, and subsequent male in 90% of transgenic , despite the absence of other Y-linked genes. This gain-of-function assay provided direct experimental proof of Sry's role as the primary sex-determining switch. Biochemical characterization confirmed SRY's mechanism: in January 1992, Harley et al. expressed recombinant human SRY protein in E. coli and showed it binds specifically to the DNA core sequence AACAAAG, inducing significant DNA bending (up to 80 degrees), a property essential for transcriptional regulation and consistent with HMG-box function. Mutations from XY females abolished this binding, linking structural integrity to biological activity. These in vitro assays elucidated SRY's action as a sequence-specific DNA architectural protein initiating downstream gene cascades like Sox9 activation.

Genetic and Structural Features

Genomic Location and Organization

The SRY gene resides on the short arm of the Y chromosome within cytogenetic band Yp11.2. In the GRCh38.p14 reference genome assembly, it spans genomic coordinates Y:2,786,855-2,787,682 on the reverse strand, encompassing approximately 828 base pairs. This positioning places SRY in the male-specific region of the Y chromosome (MSY), immediately distal to the 1 (PAR1), minimizing recombination with the . The gene exhibits a compact organization characteristic of many Y-linked loci, consisting of a single devoid of introns. The (ORF) within this exon measures 615 , encoding a 205-amino-acid protein precursor that undergoes post-translational processing. Upstream and downstream flanking sequences include minimal promoter elements and potential regulatory motifs, though the core lacks complex splicing patterns observed in autosomal genes. This intronless architecture is conserved across most mammals, reflecting the evolutionary derivation of SRY from an ancestral gene, with rare exceptions in select species where introns have been secondarily acquired or revealed as cryptic. In humans, the absence of introns facilitates rapid transcription during a narrow developmental window in the . The gene's proximity to ampliconic regions of the MSY, which contain multi-copy palindromes, underscores its integration into the structurally repetitive landscape.

Protein Architecture and Domains

The human SRY protein is a 204-amino-acid polypeptide lacking introns in its coding sequence, with its dominated by a single central high-mobility group (HMG) box domain spanning residues 57 to 140. This HMG box constitutes the sole well-defined structural domain, characterized by three α-helices stabilized by a conserved hydrophobic core, enabling specific recognition and binding to AT-rich sequences. The domain's L-shaped conformation facilitates partial intercalation of bulky residues, such as phenylalanines, into the DNA minor groove, resulting in a pronounced bend of approximately 70-80 degrees that alters . Flanking the HMG box are unstructured N-terminal (residues 1-56) and C-terminal (residues 141-204) extensions that exhibit no conserved secondary structures or globular folds in isolation, as determined by (NMR) spectroscopy and analyses. These regions, while intrinsically disordered, harbor nuclear localization signals—basic motifs at both termini—and sites for post-translational modifications, such as in the N-terminus, which modulate subcellular trafficking and transcriptional activity without forming independent domains. The absence of additional structured domains underscores SRY's reliance on the HMG box for core functionality, with terminal segments primarily serving regulatory roles in protein-protein interactions and stability. NMR-derived structures of the HMG box in complex with DNA, such as those deposited in the (e.g., PDB ID 1HRY), confirm the domain's monomeric state and flexibility outside the binding interface, with no evidence of oligomerization or auxiliary folds contributing to the protein's architecture. Full-length SRY maintains this modular design, where the terminals enhance DNA-binding efficiency by approximately 10-fold compared to the isolated HMG box, likely through electrostatic stabilization rather than structural elaboration.

Evolutionary Origins

Derivation from SOX Ancestors

The SRY protein belongs to the SOX family of transcription factors, characterized by a conserved high-mobility group (HMG) box domain that binds DNA and induces bending to facilitate transcriptional regulation. Phylogenetic evidence positions SRY as derived from SOX3, an X-linked gene primarily expressed in the developing nervous system and conserved across mammals. SOX3 exhibits the closest sequence similarity to SRY among SOX family members, with approximately 67% nucleotide identity in the HMG box coding region and shared absence of introns, indicating a direct ancestral relationship. This evolutionary derivation likely arose via duplication of SOX3 onto the proto-Y chromosome during the differentiation of in the common ancestor of therian mammals (placentals and marsupials), estimated at 160–180 million years ago. Post-duplication, SRY acquired mutations in its HMG box and regulatory regions that shifted its function toward testis-specific transcriptional activation, distinct from SOX3's broader developmental roles. across therians, including marsupials that retain a functional SRY ortholog, supports this timeline, as SRY's male-determining capability emerged after the divergence from monotremes, which lack SRY and rely on alternative mechanisms like DMRT1. Functional studies reinforce the linkage: both SRY and SOX3 HMG domains bend DNA similarly, but SRY uniquely interacts with partners like to initiate differentiation, a specialization absent in SOX3. The family's deeper origins trace to bilaterian ancestors, with HMG-box motifs predating vertebrates, but SRY's Y-linkage and sex-determining role represent a therian-specific , potentially via or regulatory neofunctionalization of the ancestral SOX3 copy.

Sequence Divergence and Conservation

The SRY protein demonstrates marked sequence divergence in its non-HMG-box regions across mammalian species, with rapid evolutionary rates observed particularly in the amino- and carboxy-terminal flanking sequences, even among closely related primates such as humans and chimpanzees. This accelerated evolution in peripheral domains contrasts sharply with the relative stasis in the core HMG-box motif, which maintains functional integrity for DNA binding despite species-specific variations. For instance, pairwise distance analyses of SRY protein sequences reveal elevated substitution rates outside the HMG box, suggesting relaxed purifying selection in these areas post-divergence from SOX ancestors. The HMG-box domain itself, comprising approximately 70-80 , exhibits substantial conservation, with identities often ranging from 70% to over 80% between distantly related mammals like humans and mice, underscoring its critical role in minor-groove DNA intercalation and bending. This domain's preservation extends to a hinge region adjacent to the box, which shows even higher conservation in some comparisons, facilitating nuclear localization and transcriptional activity. Beyond mammals, homology to SRY-like sequences diminishes rapidly in non-mammalian vertebrates, with sex-specific signals absent outside therians, indicating that full SRY functionality arose after the of mammalian lineages around 200 million years ago. Recent analyses of eutherian SRY propose a model of tolerated functional decline, where substitutions accumulate under relaxed constraints, potentially allowing adaptive tweaks in testis-determining efficiency without compromising core sex-determination cascades. Such divergence complicates cross-species functional assays, as human SRY variants may not fully recapitulate ortholog behaviors, highlighting the need for species-specific studies. Phylogenetic reconstructions further indicate that SRY's non-box sequences diverged following the gene's derivation from SOX3 on the , with Y-linkage accelerating neutral drift in unconstrained regions.

Expression and Regulatory Mechanisms

Developmental Timing and Tissue Specificity

The expression of the SRY gene, encoding the sex-determining region Y protein, is highly restricted to the somatic cells of the XY genital ridge during mammalian embryogenesis, specifically in precursors that differentiate into Sertoli cells, thereby confining its role to the initiation of testis development within the bipotential . This tissue specificity arises from cis-regulatory elements that drive SRY transcription selectively in gonadal and coelomic epithelium-derived cells, with negligible expression in germ cells or extra-gonadal tissues during the critical sex-determining phase. Aberrant extra-gonadal expression, when observed in adult tissues such as the , occurs post-developmentally and does not contribute to primary sex determination. In the mouse model, Sry transcripts emerge at embryonic day 10.5 (E10.5) in XY gonads, escalate to peak levels by E11.5 in pre-s, and terminate abruptly by E12.5, delineating a narrow temporal window of roughly 48 hours essential for activating downstream targets like Sox9. Delays in this onset exceeding 6 hours compromise Sox9 upregulation and differentiation, often resulting in partial or complete gonadal . The brevity of expression underscores its dose- and timing-dependent function, where insufficient duration fails to sustain the male developmental cascade. Human SRY expression mirrors this transience but aligns with longer gestational timelines, commencing in the 46,XY gonadal ridge between 41 and 44 days post-ovulation ( 17–18, approximately 6 weeks ), peaking at stages 19–20 (46–48 days post-ovulation), and declining thereafter, with transcripts detectable up to 9 weeks and protein persisting in Sertoli cell nuclei through at least 18 weeks. This period coincides precisely with the morphological onset of testis cord formation and specification around days 40–42 post-conception. Precise spatiotemporal control is vital, as evidenced by mutations or regulatory disruptions altering timing or levels, which precipitate 46,XY .

Factors Influencing Activation and Repression

The activation of SRY expression occurs specifically in the pre-Sertoli cells of the genital ridge during mammalian embryonic development, typically initiating around embryonic day 10.5 in mice and week 6-7 in humans, driven by a network of upstream transcription factors that bind to its proximal promoter and distal regulatory elements. Wilms' tumor 1 (WT1), particularly the -KTS isoform, directly transactivates Sry by binding to a site between -56 and -47 base pairs upstream of the transcription start site (TSS), synergizing with GATA4 to enhance promoter activity. Steroidogenic factor 1 (SF1, encoded by NR5A1) binds the SRY promoter in humans and pigs, facilitating expression in the absence of which no Sry transcription occurs in mouse gonads. GATA4 binds two motifs in the mouse Sry promoter, requiring co-activation by friend of GATA-2 (FOG2) and upstream signals from SIX1/SIX4 proteins, which upregulate Fog2; disruptions in this pathway, such as in Gata4 mutants, significantly reduce Sry levels. Epigenetic modifications prime the Sry locus for activation by establishing a permissive chromatin state. During the expression window at approximately 11.5 days post-coitum (dpc) in mice, the promoter undergoes DNA hypomethylation at five CpG sites near the TSS and gains active histone marks such as H3K4 trimethylation (H3K4me3) and H3 acetylation (H3ac), while the repressive H3K9 dimethylation (H3K9me2) mark is actively removed by the demethylase JMJD1A; failure of this demethylation, as in Jmjd1a-deficient mice, elevates H3K9me2 and impairs Sry upregulation. These changes integrate signals from three regulatory modules: one converging on GATA4 via MAPK/p38 phosphorylation and insulin signaling, another on SF1 influenced by CBX2 and CITED2, and a direct WT1 module, ensuring precise spatiotemporal initiation to trigger testis differentiation. Repression of Sry follows its transient peak expression, limiting duration to avoid disrupting downstream pathways like SOX9 autoregulation, primarily through epigenetic silencing rather than dedicated transcriptional repressors. methylation of the Sry 5'-flanking region suppresses activity, indicating as a key mechanism that re-establishes repression post-activation in gonads. This aligns with observations that Sry hypomethylation correlates with active expression, while hypermethylation silences it, as seen in cases of delayed or reduced expression leading to . Although has been hypothesized to feedback-repress Sry based on downregulation in ovotestes, direct evidence remains inconclusive, with no robust identification of specific transcriptional repressors; instead, the shift to stable male fate relies on epigenetic lockdown preventing Sry re-expression.

Molecular Function

DNA Binding via HMG Box

The HMG (high mobility group) box domain constitutes the primary DNA-binding motif of the SRY protein, spanning approximately amino acids 58 to 142 in the human sequence. This domain folds into an L-shaped structure featuring three α-helices connected by short loops, enabling it to insert into the minor groove of DNA. SRY's HMG box exhibits sequence-specific binding to A/T-rich motifs, with a consensus sequence of 5'-[AT]AACAA[AT]-3', where interactions occur primarily through hydrogen bonds to base atoms in the minor groove. Hydrophobic residues, including phenylalanine at position 109 and isoleucine at 93, partially intercalate between adjacent base pairs, widening the minor groove and distorting the DNA helix. This binding mode induces a pronounced bend in the DNA, typically ranging from 50° to 80° depending on the experimental context and flanking sequences, as measured by techniques such as circular permutation gel electrophoresis and NMR spectroscopy. The bending is facilitated by the concave surface of the HMG box, which compresses the major groove while expanding the minor groove, with recent crystal structures revealing up to 10 direct hydrogen bonds between protein side chains and DNA bases in each complex. The DNA distortion mediated by the HMG box is essential for SRY's function, as it likely promotes protein-protein interactions or chromatin remodeling to initiate downstream transcriptional events in sex determination. Mutations within the HMG box, such as those altering intercalating residues, reduce binding affinity and bending efficiency, underscoring the mechanistic precision of this domain.

Transcriptional Activation Pathways

The SRY protein exerts its transcriptional activation primarily through its high-mobility group (HMG) box domain, which binds to A/T-rich DNA sequences with low sequence specificity, inducing a sharp bend of approximately 70-80 degrees in the DNA helix. This architectural distortion facilitates the assembly of multiprotein complexes on target enhancers, enabling SRY to function as a pioneer factor that remodels chromatin accessibility in the developing gonadal ridge. The principal pathway involves SRY-mediated upregulation of SOX9, achieved by cooperative binding with (SF1, encoded by NR5A1) to the testis-specific enhancer core element of Sox9 (), a 1.4-kb regulatory approximately 5 kb upstream of the Sox9 transcription start site. This interaction, observed in mouse models around embryonic day 10.5-11.5, triggers a several-fold increase in Sox9 transcription, sufficient to shift the bipotential toward testis differentiation despite SRY's transient expression window of about 6-12 hours. SRY's activation potency is enhanced in vivo by gonadal context, including interactions with histone-modifying complexes, though isolated SRY shows modest in reporter assays (typically 2-5 fold over basal). Beyond , SRY directly regulates a subset of Sertoli cell-specific genes, sharing binding motifs with SOX9 at promoters of targets like Amh and Fgf9, thereby initiating a feed-forward cascade. Evidence from chromatin immunoprecipitation studies indicates SRY occupancy at over 100 genomic sites enriched for testis differentiation pathways, underscoring its role in coordinating multiple activation events. SRY also interacts with WD repeat domain 5 (WDR5), a subunit of MLL histone methyltransferase complexes, to synergistically boost Sox9 enhancer activity via H3K4 trimethylation. In certain species like the , conserved mechanisms extend to upregulation of ER71 (ETV2), linking SRY to vascular and endothelial gene networks that support gonadal vasculature. These pathways collectively ensure robust, threshold-dependent activation, where insufficient SRY dosage—as seen in positional variants—fails to surpass the transcriptional threshold for .

Physiological Role in Sex Determination

Triggering Sertoli Cell Differentiation

The SRY protein functions as the primary initiator of male gonad differentiation by directing the specification of pre-Sertoli cells in the XY genital ridge. In mouse models, which provide the most detailed mechanistic insights due to experimental tractability, Sry transcription begins at approximately 10.5 days post coitum (dpc) in somatic progenitor cells of the genital ridge, reaches peak levels at 11.5 dpc, and ceases by 12.5 dpc. This transient expression window is critical, as Sry activation after 11.3 dpc fails to sustain downstream programs, resulting in ovarian rather than testicular development. At the molecular level, SRY acts as a transcription factor that binds specific DNA motifs via its high-mobility group (HMG) box domain, inducing DNA bending of 60–85 degrees to facilitate chromatin remodeling and gene activation. SRY cooperates with steroidogenic factor 1 (SF1, encoded by Nr5a1) to directly target the testis-specific enhancer core element (TESCO), located 11–13 kb upstream of the Sox9 promoter, thereby driving rapid upregulation of Sox9 transcription. Sox9 expression initiates shortly after Sry onset, peaks between 11.5 and 12.5 dpc, and persists long-term in Sertoli cells. This activation is further tuned by SRY's interaction with GATA4 in a mitogen-activated protein kinase (MAPK)-dependent manner, ensuring spatiotemporal precision. Upregulation of is the pivotal event in differentiation, as directs pre-Sertoli progenitors—bipotential supporting cells that would otherwise form granulosa cells in XX gonads—toward a Sertoli fate. subsequently activates male-specific genes such as (encoding ), Fgf9, and Ptgds (prostaglandin D synthase), promoting testis cord formation and suppressing ovarian pathways like Wnt4/Rspo1 signaling. Maintenance of high levels relies on : autoregulates its own expression via SF1 binding to TESCO, amplified by FGF9 through FGFR2 and PGD2-mediated non-cell-autonomous effects on neighboring cells. Chromatin immunoprecipitation assays confirm SRY's direct occupancy at TESCO, while transgenic overexpression of Sry in XX mice induces Sox9 and Sertoli differentiation, causing full sex reversal to male phenotype. In humans, the mechanism is conserved, with SRY expression around gestational weeks 6–7 triggering analogous Sox9 activation; disruptions, such as point mutations impairing HMG binding, prevent Sertoli differentiation and lead to 46,XY complete gonadal dysgenesis. These findings underscore SRY's role as a binary switch, where insufficient or mistimed activity defaults to female development due to the inherent ovarian bias of the bipotential gonad.

Cascade Leading to Testis Formation

The sex-determining region Y (SRY) protein initiates testis formation by transiently activating expression of the transcription factor in supporting cell precursors within the bipotential around embryonic day 10.5 in mice (equivalent to approximately 6-7 weeks in humans). SRY achieves this by binding to specific enhancer elements, such as the (testis-specific enhancer core element) region upstream of SOX9, thereby recruiting co-activators and inducing SOX9 upregulation to a critical threshold that commits cells to the male pathway. Once elevated, establishes a feed-forward loop with fibroblast growth factor 9 (FGF9): directly transactivates Fgf9 expression, and FGF9 signaling in turn reinforces transcription via FGFR2 receptor activation and downstream MAPK/ERK pathways, suppressing the female-determining factor WNT4/β-catenin and preventing ovarian development. This mutual reinforcement, active from embryonic day 11.5 onward in mice, ensures robust and sustained levels essential for overriding default ovarian differentiation. Additionally, (PGD2) produced by COX2 in the coelomic amplifies independently of FGF9, further stabilizing the male cascade during this narrow temporal window. Differentiated Sertoli cells, driven by , orchestrate testis morphogenesis by secreting (AMH) from around embryonic day 12.5 in mice, which induces regression of Müllerian ducts to prevent female internal genitalia formation, while also promoting proliferation of peritubular myoid cells and endothelial progenitors. further activates genes like (Dhh), which recruits interstitial Leydig cells to produce testosterone, enabling Wolffian duct stabilization and masculinization of external genitalia. This culminates in testis cord formation through assembly and vascular remodeling, establishing the compartmentalized testicular architecture by embryonic day 13.5 in mice. Disruptions in this cascade, such as insufficient dosage, lead to partial or complete , underscoring its causal role in testis specification.

Associated Disorders

Mutations Causing 46,XY Gonadal Dysgenesis

Mutations in the SRY gene underlie approximately 10–15% of cases of 46,XY complete gonadal dysgenesis (CGD), a condition characterized by streak gonads, female external genitalia, and absence of Müllerian duct regression in individuals with a 46,XY karyotype, despite the presence of the Y chromosome. These mutations disrupt the protein's function in triggering Sertoli cell differentiation during embryonic gonadal development, preventing testis formation and leading to ovarian-like streak gonads prone to neoplastic transformation, such as gonadoblastoma. The majority of pathogenic SRY variants are de novo point mutations or small deletions concentrated in the high-mobility group (HMG) box domain, a 79-amino-acid essential for sequence-specific DNA binding and inducing DNA bending to facilitate transcriptional activation of downstream targets like SOX9. Missense mutations, such as those altering conserved residues (e.g., R62G, R75M, or I90M), abolish DNA-binding affinity or nuclear localization, as demonstrated by assays showing reduced transcriptional activity compared to wild-type SRY. Frameshift or nonsense mutations upstream of the HMG box can also truncate the protein, eliminating functional domains, while rare large deletions encompassing SRY account for additional cases. Functional studies of these variants reveal a loss-of-function mechanism, where mutated SRY fails to upregulate Sertoli cell-specific genes, halting the male gonadogenesis cascade and defaulting to female developmental pathways. In familial instances, which are uncommon, autosomal dominant inheritance with incomplete penetrance has been reported, as in a novel HMG-box mutation segregating variably across generations. Detection rates vary by cohort, with some smaller series suggesting up to 60% prevalence in select XY female populations, though broader reviews confirm the 10–15% range after excluding mosaicism or other loci like NR5A1. Genetic testing for SRY sequencing is recommended in 46,XY CGD to guide prognosis and gonadal management, given the elevated tumor risk necessitating prophylactic gonadectomy.

SRY Translocations in XX Males

46,XX testicular disorder of sex development, also known as , arises primarily from the translocation of the SRY gene from the to an , leading to male phenotypic development despite a 46,XX . In these cases, the presence of SRY on the derivative X chromosome (often denoted as der(X)t(X;Y)) triggers the differentiation of bipotential gonads into testes, mimicking the male developmental pathway typically initiated by the . Approximately 80-90% of individuals with 46,XX testicular DSD are SRY-positive, with the translocation accounting for the majority of these instances. The translocation typically occurs during paternal due to illegitimate recombination or crossover errors in the 1 (PAR1) of the , where X and Y share homology. This results in a small segment of the short arm, including SRY at Yp11.32, being transferred to the , often without significant loss of genetic material from the X. Breakpoint variability is high, with some cases involving deletions of nearby genes such as ARSE, which can contribute to associated features like . SRY-negative XX males, comprising 10-20% of cases, involve alternative mechanisms like overexpression or other upstream regulators, but translocations specifically implicate SRY as the causal driver in positive cases. Clinically, SRY-positive XX males present with normal male external genitalia at birth but often develop , due to , and during , alongside small testes (typically <4 mL volume). The condition has an estimated prevalence of 1 in 20,000 newborn males. Inheritance is rare, as affected individuals are usually sterile, preventing transmission; however, mosaicism or undetected paternal Y material can occur in exceptional families. Diagnosis relies on karyotyping to confirm 46,XX, followed by molecular testing such as PCR or fluorescence in situ hybridization (FISH) to detect SRY presence, which is crucial for distinguishing from other disorders of sex development. Cytogenetic analysis reveals the translocation breakpoint, aiding in prognostic assessment for fertility and associated risks. Variations in the SRY gene contribute to a spectrum of 46,XY disorders/differences of sex development (DSD) phenotypes beyond complete gonadal dysgenesis, including partial gonadal dysgenesis where individuals exhibit ambiguous external genitalia, incomplete testicular differentiation, and varying degrees of virilization depending on the residual function of the mutant protein. Hypomorphic SRY mutations, which retain partial transcriptional activity, are implicated in these milder phenotypes, contrasting with loss-of-function variants that result in streak gonads and female external morphology. In ovotesticular DSD, SRY protein expression has been detected in ovotestes and streak gonads of affected 46,XY individuals, indicating that dysregulated or mosaic SRY activity may permit bipotential gonadal tissue development rather than uniform testicular formation. Such cases highlight SRY's role in initiating but not fully sustaining the male differentiation cascade, with SRY variants accounting for a subset of true hermaphroditism phenotypes historically observed in up to 10-20% of ovotesticular cases involving Y-chromosome material. However, SRY mutations are identified in only approximately 15% of partial gonadal dysgenesis instances, underscoring multifactorial etiology involving downstream effectors like SOX9 or NR5A1. Broader phenotypic variability arises from SRY dosage effects, such as mosaicism or partial deletions, which can manifest as isolated hypospadias or cryptorchidism in otherwise virilized 46,XY individuals, linking SRY perturbations to subtler DSD forms. Functional studies confirm that certain SRY missense variants impair DNA binding or nuclear translocation insufficiently to abolish all activity, correlating with intermediate gonadal phenotypes rather than binary sex reversal. These associations emphasize SRY's position as a threshold-dependent trigger in gonadal fate, where quantitative or qualitative deficits expand the DSD spectrum.

Clinical and Diagnostic Applications

Genetic Screening Methods

Polymerase chain reaction (PCR) targeting SRY-specific sequences in the Yp11.3 region serves as a primary method for detecting the gene's presence or absence, particularly in ambiguous genitalia or suspected 46,XX males, with results obtainable within hours via real-time or endpoint amplification. Quantitative fluorescent PCR (QF-PCR) extends this by rapidly quantifying Y-derived markers, including SRY, to assess for sex chromosome aneuploidy or mosaicism in disorders of sex development (DSD), offering turnaround times of a few hours for initial triage. Fluorescence in situ hybridization (FISH) employs locus-specific probes to visualize SRY on metaphase or interphase cells, confirming deletions, translocations, or ectopic presence in cases like 46,XY gonadal dysgenesis or XX males, and is especially useful when PCR yields inconclusive results due to low-level mosaicism. For mutation screening, Sanger sequencing of the SRY open reading frame identifies point mutations or small indels responsible for up to 15% of 46,XY complete gonadal dysgenesis, while next-generation sequencing (NGS) panels enable deeper variant detection, including rare non-coding changes, in comprehensive DSD evaluations. In prenatal diagnostics, cell-free fetal DNA analysis via quantitative PCR detects SRY from maternal plasma as early as 7-10 weeks gestation for non-invasive sex determination, though confirmatory invasive testing like amniocentesis with PCR or array comparative genomic hybridization may follow for high-risk cases. These methods are typically performed on genomic DNA extracted from blood, buccal swabs, or amniotic fluid, with clinical labs prioritizing multiplex approaches combining PCR and sequencing for cost-effective, high-sensitivity screening in ambiguous or discordant phenotypes.

Implications for Prenatal and Postnatal Diagnosis

Detection of the SRY gene in cell-free fetal DNA from maternal plasma enables non-invasive prenatal determination of male fetal sex, with reported sensitivity of 96.6% and specificity of 98.9% across studies evaluating this method. Real-time PCR targeting SRY or multicopy markers like DYS14 on the Y chromosome facilitates this assessment as early as 7-8 weeks gestation, aiding clinical decisions for conditions such as X-linked disorders where male fetuses require further monitoring. SRY sequences can appear in maternal serum as early as day 18 post-embryo transfer in assisted reproduction cases, though persistence post-delivery necessitates confirmatory testing to avoid false positives from maternal contamination or fetal microchimerism. Limitations in prenatal SRY detection include discrepancies from Y chromosome structural variants, such as deletions encompassing SRY at Yp11.3, sex chromosome mosaicism, or aneuploidies, which can lead to false-negative male predictions in up to 1-3% of cases depending on assay sensitivity. In suspected disorders of sex development (DSD), prenatal identification of SRY-negative 46,XY profiles or absent SRY in discordant karyotypes prompts invasive follow-up like amniocentesis for full sequencing, enabling early counseling on potential gonadal dysgenesis risks. Postnatally, SRY testing via PCR or targeted sequencing confirms the presence or absence of the gene in newborns with ambiguous genitalia or phenotypic sex incongruent with karyotype, distinguishing 46,XX testicular DSD (due to SRY translocation) from 46,XY complete gonadal dysgenesis (often from SRY mutations). In 46,XY DSD cohorts, pathogenic SRY variants are identified in 10-20% of pure gonadal dysgenesis cases through next-generation sequencing, guiding prognosis for infertility and gonadoblastoma risk without relying solely on hormonal assays. Routine neonatal screening for SRY mutations is recommended in multidisciplinary DSD protocols to differentiate monogenic causes from multifactorial ones, informing surgical and endocrine management decisions within the first weeks of life.

Applications in Sex Verification

Historical Use in Olympic Testing

The International Olympic Committee (IOC) implemented polymerase chain reaction (PCR) testing for the SRY gene as a method of sex verification for female athletes beginning with the 1992 Barcelona Summer Olympics, replacing earlier Barr body and Y-chromosome fluorescence tests due to their limitations in detecting certain genetic anomalies. This genetic assay targeted the SRY locus on the Y chromosome, using DNA extracted from buccal smears to amplify and detect the presence of the gene, which encodes the sex-determining region Y protein critical for male gonadal development; an autosomal control gene, such as galactose-1-phosphate uridyltransferase, was co-amplified to validate the test. At the 1992 Games, 2,406 female athletes underwent screening, yielding 15 SRY-positive results, though outcomes remained confidential and no disqualifications resulted from misrepresentation. The SRY test continued at subsequent Olympics, including the 1996 Atlanta Games where 3,387 female athletes were screened, identifying eight SRY-positive cases—seven attributed to complete androgen insensitivity syndrome (AIS) and one to 5-alpha-reductase deficiency—all of whom were permitted to compete after clinical evaluation confirmed phenotypic female development and absence of androgen-driven advantages. Proponents viewed the test as a precise molecular marker for Y-chromosome-derived male genetic sex, aiming to exclude individuals with potential male-typical physiological benefits in women's events, yet it revealed no instances of deliberate male infiltration over thousands of tests. Limitations emerged, including false positives from contamination or technical error (e.g., one reported case at Barcelona) and failure to address exceptions like SRY-positive phenotypic females with androgen resistance, prompting ethical critiques from geneticists who argued it oversimplified biological sex determination and caused undue stigma without enhancing fairness. Mandatory SRY screening persisted through the 1998 Nagano Winter Olympics but was discontinued by the IOC in 1999 ahead of the Sydney 2000 Games, shifting to targeted, case-by-case assessments due to the protocol's discriminatory impact, lack of proven utility in preventing fraud, and scientific shortcomings such as insensitivity to mosaicism or SRY translocations in XX males. This marked the end of routine genetic sex verification in Olympic competition, reflecting broader recognition that SRY detection alone inadequately captured the interplay of genetics, hormones, and phenotype in athletic eligibility.

Modern Policies Targeting SRY Detection

In July 2025, World Athletics implemented a mandatory once-in-a-lifetime SRY gene test for all athletes seeking to compete in the female category at its World Championships and other elite events, effective from September 1, 2025, as part of eligibility regulations under Rule 3.5. The test, typically conducted via cheek swab, detects the presence of the SRY gene on the Y chromosome, which World Athletics describes as a "reliable proxy for determining biological sex" due to its role in initiating male gonadal development. A positive result renders the athlete ineligible for the female category, applicable to cases including undiagnosed 46,XY differences of sex development (DSD), transgender individuals with 46,XY karyotype, or other Y-chromosome translocations, regardless of hormone levels or phenotype. Non-compliance with testing requirements results in automatic ineligibility. By September 9, 2025, World Athletics president reported that over 95% of targeted female athletes had completed the test ahead of the World Championships in Japan, with remaining cases addressed on-site. The policy builds on prior DSD regulations focused on testosterone suppression but shifts emphasis to genetic markers for fairness, citing the SRY test's high accuracy and low risk of false positives or negatives. In cases of positive SRY detection, athletes may appeal via physical examination or further genetic analysis, but the federation maintains that SRY presence confers irreversible male developmental advantages. Following World Athletics' lead, the International Ski Federation (FIS) approved a similar gene testing policy in September 2025 for gender eligibility verification in its events, explicitly referencing SRY detection to align with athletics standards and address competitive equity in female categories. In contrast, the International Olympic Committee (IOC) has not adopted SRY-specific testing in its current framework, which emphasizes case-by-case assessments of testosterone levels and performance advantages rather than routine genetic screening since discontinuing mandatory chromosome tests in 1999. These policies reflect a targeted resurgence of SRY-focused verification in select federations amid ongoing debates over DSD eligibility, prioritizing empirical genetic evidence of male-determining mechanisms over phenotypic or self-identified criteria.

Controversies and Scientific Debates

Challenges in Defining Biological Sex

The binary nature of biological sex in humans is fundamentally tied to anisogamy, with males committed to producing small, motile sperm and females to producing large, immotile ova, a distinction mediated by the 's role in triggering testis formation during embryonic development. In typical cases, the presence of a functional SRY gene on the Y chromosome bends the bipotential gonad toward differentiation around weeks 6-7 of gestation, initiating male gonadal and ductal development; its absence defaults to ovarian formation and female pathways. This genetic switch, identified as the testis-determining factor in 1990 through linkage to Y-chromosomal translocations in , provides a mechanistic basis for sex dimorphism conserved across mammals. Challenges emerge in disorders of sex development (DSDs), where rare genetic anomalies disrupt the usual genotype-phenotype concordance, complicating definitions reliant solely on karyotype or external morphology. For example, point mutations or deletions in SRY, occurring in approximately 10-15% of 46,XY gonadal dysgenesis cases (Swyer syndrome), impair DNA-binding via its HMG domain, preventing testis induction and resulting in female-typical external genitalia despite XY chromosomes; affected individuals develop streak gonads incapable of gamete production. Reciprocally, upstream translocations of SRY to an X chromosome during paternal meiosis produce 46,XX males with testicular tissue, albeit often infertile due to azoospermia from lacking other Y-linked genes like those in the AZF regions. These approximately 1 in 20,000 incidence events underscore that sex determination hinges on SRY functionality rather than chromosome count alone, as evidenced by de novo mutations correlating with complete sex reversal. Such exceptions, while highlighting the pathway's vulnerability to molecular perturbations, do not negate the binary paradigm, as no human produces both gamete types or functional intermediates; DSD individuals are sterile or unidirectionally impaired, aligning with disrupted male or female trajectories. Attempts to frame these pathologies as evidence for a sex "spectrum" often stem from interpretations prioritizing phenotypic variability over reproductive criteria, a view critiqued in genetic literature for conflating rare disorders (affecting <0.02% for SRY-related reversals) with normative biology. Empirical data from over 100 documented SRY variants affirm its causal primacy, with downstream failures (e.g., in SOX9 or NR5A1) similarly yielding binary outcomes rather than ambiguity. Thus, definitional challenges reflect diagnostic precision needs in clinical contexts, not ontological fluidity, as sex remains anchored in gametic dimorphism irrespective of SRY perturbations.

Disputes Over Athletic Eligibility Criteria

In 2025, World Athletics implemented a mandatory once-in-a-lifetime SRY gene test via cheek swab or dried blood spot for all athletes seeking to compete in the female category at its World Championships, rendering those with a positive result ineligible for that category and directing them instead to male or newly introduced open categories where applicable. The policy, effective from September 1, 2025, positions the SRY test as a definitive marker of biological male development potential, bypassing prior reliance on testosterone thresholds that had faced legal challenges, such as those from athletes with differences of sex development (DSD). Proponents argue this addresses persistent fairness issues, as the SRY protein initiates testis formation and subsequent androgen-driven puberty, conferring irreversible advantages in strength, speed, and power—evidenced by male athletes outperforming females by 10-30% across most track and field events even after accounting for training. The core dispute centers on whether SRY detection reliably proxies athletic advantage, with supporters citing causal links from SRY-mediated male gonadal development to elevated testosterone (up to 30 times higher in males), which drives greater muscle mass, hemoglobin levels, and skeletal robusticity before adolescence. In XY DSD cases with functional SRY, such as 5-alpha reductase deficiency seen in athletes like , these traits manifest despite variable testosterone regulation, contributing to dominance in events like the 800m, where Semenya's performances exceeded typical female ranges post-2009 scrutiny. Empirical data from elite competitions reinforce this, showing XY athletes with DSD retaining edges in oxygen transport and force production that hormone suppression post-puberty does not fully mitigate. World Athletics Council President emphasized the test's high accuracy, with false positives or negatives deemed "extremely unlikely," and reported 90% compliance among female-category athletes by August 2025. Critics, including the European Society of Human Genetics, contend the SRY test oversimplifies complex DSD phenotypes, potentially barring athletes like those with Swyer syndrome (XY karyotype with non-functional SRY mutations leading to female gonadal dysgenesis and no androgenization) or (CAIS), where androgen receptors fail despite SRY-driven testes, resulting in minimal performance edges beyond height. Organizations such as OII Europe and Human Rights Watch have labeled the policy discriminatory, arguing it revives stigmatizing sex verification practices without individualized assessment and conflates transgender athletes (who retain SRY if XY-origin) with innate DSD variations, exacerbating mental health burdens on affected individuals. However, such critiques often prioritize inclusion over empirical performance disparities, with studies indicating that even in CAIS, Y-linked factors correlate with advantages in non-androgen-dependent traits like aerobic capacity. Legal challenges persist, echoing the 2023 Court of Arbitration for Sport rulings on testosterone rules, but World Athletics maintains the SRY criterion upholds the female category's integrity against male physiological baselines. Similar policies have emerged in World Boxing, signaling broader adoption amid ongoing debates.

Current Research Directions

Analysis of Pathogenic Variants

Pathogenic variants in the SRY gene primarily disrupt the protein's function as a transcription factor, leading to failure of testis differentiation in 46,XY individuals and resulting in complete gonadal dysgenesis (Swyer syndrome), characterized by streak gonads, female external genitalia, and absence of spontaneous puberty. These variants account for 10-15% of 46,XY gonadal dysgenesis cases, with over 100 distinct mutations documented, the vast majority occurring de novo or inherited via the Y chromosome. Most pathogenic variants localize to the high-mobility group (HMG) box domain, a 79-amino-acid region critical for sequence-specific DNA binding, minor groove bending, and recruitment of downstream effectors like to initiate Sertoli cell differentiation. Missense mutations in this domain, such as p.Met85Thr, impair nuclear localization by altering the protein's import signals, while nonsense variants like p.Arg86Ter produce truncated, undetectable proteins lacking functional HMG domains. Frameshift mutations, exemplified by p.Tyr198Cysfs*18 in the C-terminal region, lead to elongated or unstable polypeptides that fail to transactivate target genes, though the precise mechanism may involve disrupted post-translational modifications or interactions beyond DNA binding. Functional assays consistently demonstrate loss-of-function effects: for instance, the nonsense mutation c.293G>A (p.Trp98*) truncates the protein within the HMG box, abolishing DNA interaction and causing primary amenorrhea with elevated gonadotropins in affected 46,XY females. However, not all bioinformatically predicted damaging variants exhibit uniform impairment; p.Asp58Glu and p.Arg75Lys, both in the HMG box, retain near-normal nuclear localization and transactivation in cell-based models, suggesting modifier effects, mosaicism, or assay limitations may contribute to phenotype in vivo, warranting cautious interpretation of pathogenicity. Rarer variants outside the HMG box, such as those affecting nuclear localization signals, similarly block SRY's translocation to the nucleus, preventing the transient, gonad-specific expression pulse required for male sex determination around embryonic week 6-7. Partial phenotypes are less common with SRY variants, which typically yield complete , underscoring the gene's binary switch-like role; incomplete in familial cases may reflect dosage sensitivity or environmental modulators.

Models and Potential Interventions

Mouse models have been pivotal in elucidating SRY function, with via TALEN in pronuclear-stage oocytes producing XY offspring that develop ovaries and female phenotypes, confirming SRY's necessity for testis differentiation. Similarly, /Cas9-mediated knock-in of murine Sry at specific loci has enabled stable transgenic lines to study regulatory elements and protein domains essential for sex determination. Transgenic XX harboring human SRY transgenes develop testes and characteristics, demonstrating SRY sufficiency across , while -edited variants reveal critical motifs like the HMG box for DNA binding and upregulation. Porcine models, including HMG domain knockouts via , exhibit complete in genetic , producing female genitalia and validating SRY's conserved role in mammals beyond . In vitro and ex vivo systems complement animal models; for instance, targeting Sry in developing gonads downregulates expression, inducing partial sex reversal and highlighting temporal sensitivity during embryonic gonadal ridges. These models underscore SRY's mechanism as a transcriptional activator that bends DNA to initiate differentiation, with disruptions mimicking human . Potential interventions for SRY-related disorders, such as mutations causing complete in XY individuals, remain preclinical, focusing on editing to restore function. CRISPR-based correction of pathogenic variants in cellular models holds promise, as demonstrated by precise knock-in achieving functional SRY expression without off-target effects in mice. However, no clinical therapies targeting SRY exist as of 2025, with current limited to replacement and prophylactic gonadectomy due to malignancy risk; experimental RNAi or editing approaches, while effective in reversing sex determination in models, raise ethical and safety concerns for application. Agricultural contexts explore SRY knockouts for uniform female , but therapeutic translation requires addressing delivery challenges and mosaicism.

References

  1. https://medlineplus.gov/genetics/gene/sry/
  2. https://omim.org/entry/480000
  3. https://www.ncbi.nlm.nih.gov/books/NBK22246/
  4. https://www.uniprot.org/uniprotkb/Q05066/entry
  5. https://journals.biologists.com/dev/article/137/23/3921/44191/Sry-the-master-switch-in-mammalian-sex
  6. https://www.nature.com/articles/346240a0
  7. https://www.nature.com/articles/348448a0
  8. https://link.springer.com/article/10.1007/s10577-011-9256-x
  9. https://www.science.org/doi/10.1126/science.abb6430
  10. https://www.nature.com/articles/351117a0
  11. https://www.science.org/doi/10.1126/science.1734522
  12. https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core%3Bg=ENSG00000184895
  13. https://www.ncbi.nlm.nih.gov/gene/6736
  14. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SRY
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC19134/
  16. https://www.sciencedirect.com/topics/neuroscience/sry-gene
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC1484449/
  18. https://www.rcsb.org/structure/1j46
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC4239596/
  20. https://www.embopress.org/doi/10.1002/j.1460-2075.1992.tb05551.x
  21. https://academic.oup.com/nar/article/24/6/1047/1017434
  22. https://academic.oup.com/molehr/article/14/6/325/1040125
  23. https://www.rcsb.org/structure/1HRY
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2700755/
  25. https://pubmed.ncbi.nlm.nih.gov/8111369/
  26. https://bmcecolevol.biomedcentral.com/articles/10.1186/s12862-018-1119-z
  27. https://pubmed.ncbi.nlm.nih.gov/8127908/
  28. https://pubmed.ncbi.nlm.nih.gov/11404013/
  29. https://anatomypubs.onlinelibrary.wiley.com/doi/10.1002/dvdy.23887
  30. https://journals.biologists.com/dev/article/122/2/509/38935/A-comparison-of-the-properties-of-Sox-3-with-Sry
  31. https://www.nature.com/articles/364713a0
  32. https://pubmed.ncbi.nlm.nih.gov/7890177/
  33. https://genesdev.cshlp.org/content/5/12b/2567.full.pdf
  34. https://journals.physiology.org/doi/10.1152/ajpregu.00645.2010
  35. https://pubmed.ncbi.nlm.nih.gov/1916759/
  36. https://www.sciencedirect.com/science/article/pii/S037811192500633X
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5771129/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3217241/
  39. https://pubmed.ncbi.nlm.nih.gov/11085593/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4034426/
  41. https://journals.biologists.com/dev/article/136/1/129/65122/A-critical-time-window-of-Sry-action-in-gonadal
  42. https://www.ncbi.nlm.nih.gov/books/NBK279001/
  43. https://www.sciencedirect.com/science/article/pii/S092547739900307X
  44. https://rep.bioscientifica.com/view/journals/rep/130/5/1300603.pdf
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC5698446/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4233110/
  47. https://pubmed.ncbi.nlm.nih.gov/14978045/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC6084468/
  49. https://pubmed.ncbi.nlm.nih.gov/11563911/
  50. https://www.jbc.org/article/S0021-9258%2824%2902184-7/fulltext
  51. https://www.rcsb.org/structure/9BVD
  52. https://pubmed.ncbi.nlm.nih.gov/1425584/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC4437563/
  54. https://www.sciencedirect.com/science/article/pii/S0021925820474472
  55. https://www.ncbi.nlm.nih.gov/books/NBK6504/
  56. https://www.nature.com/articles/srep32874/
  57. https://pubmed.ncbi.nlm.nih.gov/7838151/
  58. https://pubmed.ncbi.nlm.nih.gov/25088423/
  59. https://www.sciencedirect.com/science/article/pii/S2211124714005579
  60. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034327
  61. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.945030/full
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC11063913/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC4075598/
  64. https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-023-09334-0
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC7804473/
  66. https://karger.com/hrp/article/75/1/26/162538/The-Role-of-SRY-Mutations-in-the-Etiology-of
  67. https://medlineplus.gov/genetics/condition/swyer-syndrome/
  68. https://www.ncbi.nlm.nih.gov/books/NBK539886/
  69. https://academic.oup.com/jcem/article/82/2/701/2823557
  70. https://www.sciencedirect.com/science/article/abs/pii/S1769721206000437
  71. https://www.sciencedirect.com/science/article/pii/S0303720725000097
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC1682856/
  73. https://www.biorxiv.org/content/10.1101/2021.05.05.442859v1.full
  74. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040858
  75. https://www.orpha.net/en/disease/detail/242
  76. https://medlineplus.gov/genetics/condition/46xx-testicular-difference-of-sex-development/
  77. https://link.springer.com/article/10.1007/s44162-023-00025-8
  78. https://molecularcytogenetics.biomedcentral.com/articles/10.1186/s13039-019-0456-y
  79. https://onlinelibrary.wiley.com/doi/10.1111/andr.13279
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC6827185/
  81. https://www.sciencedirect.com/science/article/pii/S2214624524000200
  82. https://pubmed.ncbi.nlm.nih.gov/36617173/
  83. https://pubmed.ncbi.nlm.nih.gov/31745530/
  84. https://pubmed.ncbi.nlm.nih.gov/11173859/
  85. https://karger.com/hrp/article/96/2/180/835112/Ovotesticular-Difference-of-Sex-Development
  86. https://www.nature.com/articles/s41598-022-21718-y
  87. https://pubmed.ncbi.nlm.nih.gov/23866278/
  88. https://pubmed.ncbi.nlm.nih.gov/24854532/
  89. https://jcrpe.org/articles/current-diagnostic-approaches-in-the-genetic-diagnosis-of-disorders-of-sex-development/jcrpe.galenos.2024.2024-3-3
  90. https://ispae-jped.com/genetic-diagnosis-in-xy-disorders-of-sex-development/
  91. https://www.mayocliniclabs.com/test-catalog/overview/35301
  92. https://www.ncbi.nlm.nih.gov/gtr/tests/529046/
  93. https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-13-108
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC11629718/
  95. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pd.4078
  96. https://www.invitae.com/us/providers/test-catalog/gene-20975
  97. https://www.blueprintgenetics.com/tests/single-gene-tests/sry-single-gene-test/
  98. https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-5-476
  99. https://www.nature.com/articles/gim20118
  100. https://pubmed.ncbi.nlm.nih.gov/12871892/
  101. https://academic.oup.com/jes/article/9/2/bvaf007/7952048
  102. https://e-century.us/files/ijcem/10/1/ijcem0019103.pdf
  103. https://www.mayocliniclabs.com/test-catalog/download-setup?format=pdf&unit_code=35301
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC11408751/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC2500237/
  106. https://www.gimjournal.org/article/S1098-3600(21)00234-3/pdf
  107. https://pubmed.ncbi.nlm.nih.gov/22164600/
  108. https://worldathletics.org/news/press-releases/sry-gene-test-athletes-female-category
  109. https://www.bbc.com/sport/athletics/articles/c9d07jq6vpeo
  110. https://assets.aws.worldathletics.org/document/688a175005020be5dc97f90a.pdf
  111. https://worldathletics.org/download/download?filename=0a7afe9e-9998-4cbc-a8c5-82c0ac5a80c6.pdf&urlslug=C3.5A%2520-%2520Regulations%2520for%2520the%2520Implementation%2520of%2520Eligibility%2520Rule%25203.5%2520%28Male%2520and%2520Female%2520Categories%29%252C%2520effective%252001%2520SEP%25202025
  112. https://www.reuters.com/sports/coe-confirms-95-female-athletes-complete-gene-tests-with-rest-be-done-japan-2025-09-09/
  113. https://www.espn.com/olympics/trackandfield/story/_/id/45859752/female-athletes-take-gene-tests-track-field-worlds
  114. https://www.sportresolutions.com/news/fis-gene-testing-policy-gender
  115. https://pubmed.ncbi.nlm.nih.gov/8272686/
  116. https://www.bmj.com/content/390/bmj.r1698
  117. https://www.nas.org/academic-questions/33/2/in-humans-sex-is-binary-and-immutable/pdf
  118. https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.4706
  119. https://geneticliteracyproject.org/2025/06/10/viewpoint-utter-nonsense-a-biologists-view-of-the-presidents-declaration-defining-biological-sex/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC2725752/
  121. https://www.researchgate.net/publication/366501737_Biological_sex_is_binary_even_though_there_is_a_rainbow_of_sex_roles_Denying_biological_sex_is_anthropocentric_and_promotes_species_chauvinism
  122. https://theparadoxinstitute.org/read/a-response-to-natures-sex-redefined
  123. https://academic.oup.com/hmg/article/27/7/1228/4823478
  124. https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=5028&context=lcp
  125. https://pubmed.ncbi.nlm.nih.gov/37772882/
  126. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/dta.3876
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC6391653/
  128. https://www.skysports.com/more-sports/athletics/news/29175/13420229/world-athletics-championships-seb-coe-reveals-sry-test-receives-90-per-cent-uptake-by-athletes-in-female-categories
  129. https://www.eshg.org/news/news-details?tx_news_pi1%255Baction%255D=detail&tx_news_pi1%255Bcontroller%255D=News&tx_news_pi1%255Bnews%255D=81&cHash=4623c0a023cac2fdadac3ab05861c2cd
  130. https://www.oiieurope.org/world-athletics-decides-to-mandate-sex-testing-for-women-athletes/
  131. https://www.hrw.org/report/2020/12/04/theyre-chasing-us-away-sport/human-rights-violations-sex-testing-elite-women
  132. https://link.springer.com/article/10.1007/s40279-014-0249-8
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC7616231/
  134. https://www.reuters.com/sports/world-athletics-mandates-gene-test-female-category-eligibility-2025-07-30/
  135. https://pmc.ncbi.nlm.nih.gov/articles/PMC8385684/
  136. https://academic.oup.com/jcem/article/87/7/3428/2847396
  137. https://www.nature.com/articles/srep03136
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC6021606/
  139. https://onlinelibrary.wiley.com/doi/full/10.1002/humu.24318
  140. https://pmc.ncbi.nlm.nih.gov/articles/PMC7812820/
  141. https://pmc.ncbi.nlm.nih.gov/articles/PMC3303865/
  142. https://www.pnas.org/doi/10.1073/pnas.2008743118
Add your contribution
Related Hubs
User Avatar
No comments yet.